Text Size

Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism

This study has been completed.
Sponsor:
Information provided by:
Gulhane School of Medicine
ClinicalTrials.gov Identifier:
NCT01107067
First received: April 19, 2010
Last updated: NA
Last verified: May 2008
History: No changes posted
  Purpose

The purpose of this study is investigating the effect of testosterone treatment on paraoxonase level in male patients with hypogonadotrophic hypogonadism


Condition Intervention Phase
Hypogonadism
 Drug: Sustanon
 Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
Official Title: Phase IV Study to Investigate the Effect of Testosterone Treatment on Paraoxonase Level in Male Patients With Hypogonadotrophic Hypogonadism

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Gulhane School of Medicine:

Primary Outcome Measures:
  • paraoxonase level after testosterone treatment

Enrollment: 32
Study Start Date: June 2008
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: testosterone replacement therapy Drug: Sustanon
250 mg/21 days
Other Name: no name

  Eligibility

Ages Eligible for Study:   20 Years to 25 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Volunteers patients with hypogonadism

Exclusion Criteria:

  • Coronary heart disease
  • Other pituitary/hypothalamic disorders or other non-hypogonadism diseases
  • None was receiving vitamins, lipid-lowering drugs, or other medications known to interfere with PON1 activity, lipid profile, or gonadal function
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01107067

Locations
Turkey
Aydoğan AYDOĞDU
Ankara, Turkey, 06600
Sponsors and Collaborators
Gulhane School of Medicine
  More Information

No publications provided

Responsible Party: Gulhane School of Medicine Department of Endocrinology and Metabolism
ClinicalTrials.gov Identifier: NCT01107067     History of Changes
Other Study ID Numbers: aa001
Study First Received: April 19, 2010
Last Updated: April 19, 2010
Health Authority: Turkey: Ministry of Health

Keywords provided by Gulhane School of Medicine:
hypogonadism
paraoxonase
Hipogonadism

Additional relevant MeSH terms:
Hypogonadism
Gonadal Disorders
Endocrine System Diseases
Testosterone
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Methyltestosterone
Androgens
 Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Therapeutic Uses
Anabolic Agents

ClinicalTrials.gov processed this record on May 19, 2013